Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study
<strong>Background</strong> The recombinant vesicular stomatitis virus (rVSV) vaccine expressing the Zaire Ebola virus (ZEBOV) glycoprotein is efficacious in the weeks following single-dose injection, but duration of immunity is unknown. We aimed to assess antibody persistence at 1 and 2...
Main Authors: | Huttner, A, Agnandji, S, Combescure, C, Fernandes, J, Bache, E, Kabwende, L, Ndungu, F, Brosnahan, J, Monath, T, Lemaître, B, Grillet, S, Botto, M, Engler, O, Portmann, J, Siegrist, D, Bejon, P, Silvera, P, Kremsner, P, Siegrist, C, Krishna, S, Addo, M, Becker, S, Krähling, V, Njuguna, P, Kieny, M, Ahmed, R, Anderson, J, Auderset, F, Borgianni, L, Ciabattini, A, Haks, M, Harandi, A, Heppner, D, Gerlini, A, Medaglini, D, Ottenhoff, T, Pejoski, D, Page, M, Pozzi, G, Santoro, F, Dubey, S, Nakaya, H, Orourke, F, Rothenberger, S |
---|---|
Format: | Journal article |
Published: |
Elsevier
2018
|
Similar Items
-
Rapid dose-dependent Natural Killer (NK) cell modulation and cytokine responses following human rVSV-ZEBOV Ebolavirus vaccination
by: Pejoski, D, et al.
Published: (2020) -
Durability of single-dose rVSV-ZEBOV vaccine responses: what do we know?
by: Angela Huttner, et al.
Published: (2018-12-01) -
Dose-dependent T-cell Dynamics and Cytokine Cascade Following rVSV-ZEBOV Immunization
by: Christine Dahlke, et al.
Published: (2017-05-01) -
Transcriptomic signatures induced by the Ebola virus vaccine rVSVΔG-ZEBOV-GP in adult cohorts in Europe, Africa, and North America: a molecular biomarker study
by: Vianello, E, et al.
Published: (2021) -
Global blood miRNA profiling unravels early signatures of immunogenicity of Ebola vaccine rVSVΔG-ZEBOV-GP
by: Eleonora Vianello, et al.
Published: (2023-12-01)